Zomedica Business Summary

Zomedica Corp. (ZOMDF) operates as a veterinary health technology company that generates revenue through a hybrid model of capital equipment sales, recurring high-margin consumable transactions, and specialized engineering services. The company’s business is organized into three primary segments: Diagnostics, which includes the TRUFORMA point-of-care platform, TRUVIEW digital cystoscopy, and VetGuardian remote monitoring; Therapeutic Devices, featuring the PulseVet shock wave and Assisi tPEMF systems; and a newly established Development Services segment focused on contract manufacturing for human and animal health partners. Zomedica competes directly with industry giants such as IDEXX Laboratories, Antech Diagnostics (a division of Mars Petcare), and Merck Animal Health. Within this landscape, Zomedica distinguishes itself as a high-growth, niche innovator that prioritizes in-clinic, point-of-care diagnostic accuracy and non-invasive therapeutic solutions to reduce reliance on external reference laboratories. Founded in 2015 by Gerald Solensky Jr., Zomedica is currently led by a management team with deep expertise in medical device commercialization. President and CEO Larry Heaton brings over 35 years of executive experience from firms such as United States Surgical Corporation and Flowonix, while Chief Operating Officer Tony Blair and Vice President of Technology Innovation Evan St. Peter oversee the company’s operational scaling and R&D pipeline. The leadership team is supported by a board of directors chaired by Jeff Rowe and including former CEO Robert Cohen, alongside notable industry veterans like Dr. Pam Nichols. While the company maintains a broad retail investor base, its strategic direction is heavily influenced by its transition into a diversified multi-product platform, bolstered by the 2023 acquisition of Qorvo Biotechnologies' assets and a 2026 manufacturing partnership with Rahm Sensor Development.